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Abstract 
Background: Pre-existing comorbidities have been linked to SARS-CoV-2 infection but evidence is sparse on the 
importance and pattern of multimorbidity (2 or more conditions) and severity of infection indicated by hospitalisation 
or mortality. We aimed to use a multimorbidity index developed specifically for COVID-19 to investigate the associa-
tion between multimorbidity and risk of severe SARS-CoV-2 infection.
Methods: We used data from the UK Biobank linked to laboratory confirmed test results for SARS-CoV-2 infection 
and mortality data from Public Health England between March 16 and July 26, 2020. By reviewing the current litera-
ture on COVID-19 we derived a multimorbidity index including: (1) angina; (2) asthma; (3) atrial fibrillation; (4) cancer; 
(5) chronic kidney disease; (6) chronic obstructive pulmonary disease; (7) diabetes mellitus; (8) heart failure; (9) hyper-
tension; (10) myocardial infarction; (11) peripheral vascular disease; (12) stroke. Adjusted logistic regression models 
were used to assess the association between multimorbidity and risk of severe SARS-CoV-2 infection (hospitalisation/
death). Potential effect modifiers of the association were assessed: age, sex, ethnicity, deprivation, smoking status, 
body mass index, air pollution, 25‐hydroxyvitamin D, cardiorespiratory fitness, high sensitivity C-reactive protein.
Results: Among 360,283 participants, the median age was 68 [range 48–85] years, most were White (94.5%), and 
1706 had severe SARS-CoV-2 infection. The prevalence of multimorbidity was more than double in those with severe 
SARS-CoV-2 infection (25%) compared to those without (11%), and clusters of several multimorbidities were more 
common in those with severe SARS-CoV-2 infection. The most common clusters with severe SARS-CoV-2 infection 
were stroke with hypertension (79% of those with stroke had hypertension); diabetes and hypertension (72%); and 
chronic kidney disease and hypertension (68%). Multimorbidity was independently associated with a greater risk of 
severe SARS-CoV-2 infection (adjusted odds ratio 1.91 [95% confidence interval 1.70, 2.15] compared to no multimor-
bidity). The risk remained consistent across potential effect modifiers, except for greater risk among older age. The 
highest risk of severe infection was strongly evidenced in those with CKD and diabetes (4.93 [95% CI 3.36, 7.22]).
Conclusion: The multimorbidity index may help identify individuals at higher risk for severe COVID-19 outcomes and 
provide guidance for tailoring effective treatment.
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Background
The novel coronavirus SARS-CoV-2 has led to a global 
pandemic of a complex, pneumonia-related illness 
(COVID-19). As of 29th September 2020, there have 
been 33,749,599 confirmed cases of COVID-19 and 
1,009,829 deaths reported worldwide [1]. Many coun-
tries are still facing a devastating rise in the number of 
cases and deaths, whilst some are facing a second wave 
such as France, Spain, UK, with significant impacts 
on their healthcare systems. The risk of SARS-CoV-2 
infection is based on the person-to-person transmis-
sion rate at which the virus is circulating in the com-
munity [2, 3]. Yet, while some individuals recover from 
the SARS-CoV-2 infection, others develop severe ill-
ness which may require intensive care in hospital or 
result in mortality.
Several potential factors have been postulated or 
associated with the increased risk of transmission and 
development of severe SARS-CoV-2 infection, such as 
age, sex, ethnicity, body mass index (BMI), smoking, 
deprivation, pre-existing comorbidities (particularly 
diabetes, hypertension and cardiovascular disease), car-
diorespiratory fitness, 25‐hydroxyvitamin D level, air 
pollution and inflammation [4]. However, individuals 
with pre-existing health conditions have been found to 
have the highest risk of developing severe SARS-CoV-2 
infection, as shown in a number of studies from early 
research based in Wuhan [5] to recent studies across 
the globe [6–8]. Nevertheless, the majority of research 
to date has focused on pre-existing single chronic con-
ditions [9], yet individuals often have multiple chronic 
conditions, known as multimorbidity. In view of the 
rapidly increasing prevalence of severe SARS-CoV-2 
infection across the globe, clarifying the pattern and 
impact of multimorbidity (defined as 2 or more condi-
tions) on the risk of severe SARS-CoV-2 infection has 
important clinical and public health implications which 
are not captured by a focus on single diseases [10].
There are a number of methods to define multimor-
bidity, which include both simple measures such as 
summing up the diseases and more complex measures 
using a weighted score such as the Charles Comorbidity 
Index. A previous study in UK Biobank examined the 
pattern of the most prevalent clusters of multimorbidity 
in those infected with SARS-CoV-2, using 36 different 
conditions to define multimorbidity [11], though this 
masked the most relevant conditions related to SARS-
CoV-2 [12]. Moreover, three studies which assessed the 
risk of multimorbidity and COVID-19 had also used a 
broad range of conditions (ranging from 19 to 43 con-
ditions) [13–15]. In contrast, the available evidence 
indicates that certain health conditions are associated 
with a much greater risk of severe SARS-CoV-2 infec-
tion linked with hospitalisation or mortality [5, 16].
To help clarify the evidence, in this study we aimed to 
firstly develop a multimorbidity index of the most com-
monly reported chronic conditions from the current lit-
erature for severe SARS-CoV-2 infection. The index was 
then used to investigate the patterns and association 
between multimorbidity and risk of severe SARS-CoV-2 
infection and we further tested whether this association 
was modified by other potential risk factors.
Methods
This study is reported as per the Strengthening the 
Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines (Additional File 1: Checklist S1) 
and following a pre-specified protocol (Application 
Number 36371) [17].
Study population
UK Biobank included half a million middle-aged adults 
recruited from 22 sites across England, Wales and Scot-
land with baseline measures collected between 2006 and 
2010, from an in-person baseline interview at the UK 
Biobank centre (http:// bioba nk. ctsu. ox. ac. uk/ cryst al/ 
search. cgi). Written informed consent was obtained prior 
to data collection; UK Biobank was approved by the NHS 
National Research Ethics Service (16/NW/0274; ethics 
approval for UK Biobank studies) [18].
SARS-CoV-2 laboratory confirmed test results and 
death data for all-cause mortality from Public Health 
England were linked to the UK Biobank database [19]. 
Data were available between March 16 and July 26, 2020, 
restricted to those tested in a hospital (pillar 1), since this 
can be regarded as a proxy for hospitalisations for severe 
cases of the disease as suggested by the linkage method-
ology [19]. Our analytical sample included study partici-
pants from England as testing was available and linked, 
we therefore excluded study members from Scotland and 
Wales, participants who had an outpatient test positive 
for COVID-19 (pillar 2) as the outcome for SARS-CoV-2 
infection was uncertain (i.e. recovered, hospitalised at 
a later stage, or died), those who died before March 16, 
2020, and those with missing data (Additional file 1: Fig. 
S1).
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Multimorbidity index
To use prior evidence on comorbidities that cluster 
together and that may act in combination to affect the 
risk of COVID-19, we carried out a literature search to 
identify the most common pre-existing comorbidities in 
patients with severe SARS-CoV-2 infection (Additional 
file  1: Table  S1). The studies from the literature search 
were found to be very heterogeneous, therefore it was 
not possible to do a quantitative meta-analysis of pooled 
results [5–8, 20–29]. From a semi-quantitative perspec-
tive, we selected the most common conditions to create 
a multimorbidity index for severe COVID-19 including 
the following conditions: (1) angina; (2) asthma; (3) atrial 
fibrillation; (4) cancer; (5) chronic kidney disease (CKD); 
(6) chronic obstructive pulmonary disease (COPD); (7) 
diabetes mellitus; (8) heart failure; (9) hypertension; (10) 
myocardial infarction; (11) peripheral vascular disease; 
and (12) stroke. Data on these comorbidities were avail-
able in UK Biobank together with the clinical marker of 
CKD, the estimated Glomerular Filtration Rate (eGFR) 
value less than 60  mL/min/1.73  m2. Those with two 
or more of these conditions clustering together were 
defined as having multimorbidity and the remainder 
without multimorbidity.
Outcome measure
The outcome was severe SARS-CoV-2 infection, defined 
as admission to hospital with a positive SARS-CoV-2 
infection test result or death occurring within the study 
period of March 16 to July 26 July, 2020. The comparison 
group without severe SARS-CoV-2 infection included 
participants with negative test result for SARS-CoV-2 
either in a hospital setting or as outpatient, or having 
not been tested. Participants who received a positive 
test outside of a hospital setting were excluded from this 
analysis, as their outcome was uncertain (i.e. recovered, 
hospitalised at a later stage, or died).
Effect modifiers
The association between multimorbidity and severe 
SARS-CoV-2 infection was assessed across levels of ten 
prespecified potential effect modifiers based on the liter-
ature [4], including: (1) age at test (grouped as < 60 years 
or ≥ 60  years; (2) sex; (3) ethnicity (self-reported and 
grouped as white or non-white); (4) Townsend depri-
vation index (used to measure socio-economic status, 
which combines census data on housing, employment, 
and social class based on the postal code of partici-
pants; a higher Townsend score equates to higher lev-
els of socioeconomic deprivation and participants were 
split in two groups based on the sample median: least or 
most deprived); (5) body mass index (BMI), following the 
exclusion of individuals in the underweight [< 18.5  kg/
m2] group (n = 2093), since < 1% of the participants were 
categorised as underweight; the remaining participants 
were grouped as: normal weight [18.5–24.9  kg/m2], 
overweight [25–29.9  kg/m2], or obese [≥ 30  kg/m2]); 
(6) smoking (current smoker, previous smoker or never 
smoked at the time of assessment); (7) the annual average 
air pollution, measured by the concentrations of nitro-
gen dioxide  (NO2); data for the earliest year when the 
participant attended the assessment centre was used. We 
used the World Health Organization (WHO) guideline 
threshold of 40  µg/m3 (annual mean) which was set as 
the level for protecting the public from the health effects 
of gaseous pollutants, with values ≥ 40  µg/m3 assigned 
as high [30]; (8) serum 25-hydroxyvitamin D (25(OH)
D) concentration, a measure of vitamin D status, was 
measured at a central laboratory and further details of 
biochemical assays are provided elsewhere (http:// bioba 
nk. ctsu. ox. ac. uk/ cryst al/ refer. cgi? id= 5636). In line with 
the recommendation to maintain sufficient amounts of 
blood vitamin D levels at ≥ 25 nmol/L in the vast major-
ity (97.5%) of the population in the UK [31], participants 
were grouped as clinically deficient (< 25 nmol/L), or suf-
ficient (≥ 25  nmol/L) based on their 25(OH)D level; (9) 
cardiorespiratory fitness, defined by self-reported walk-
ing pace (slow walking pace, or steady-brisk walking pace 
[32]); and (10) the inflammatory marker high sensitiv-
ity C-reactive protein (CRP, normal [< 3  mg/L] or high 
[≥ 3 mg/L]) based on clinical recommendations [33].
Statistical analyses
We examined the baseline descriptive characteristics 
of the UK Biobank cohort among participants with and 
without severe SARS-CoV-2 infection. The age at the 
time of SARS-CoV-2 test was calculated using the base-
line date and the test date. Continuous variables were 
presented as means and standard deviations, and the cat-
egorical variables presented as counts and percentages. 
Complete case framework was used for all analyses. A 
heat map was created to illustrate the pattern of the most 
common clusters of multimorbidity by severe SARS-
CoV-2 infection and the remaining cohort. The propor-
tion and date of those with severe SARS-CoV-2 infection 
by multimorbidity was also illustrated to understand the 
pattern over the time of the pandemic.
The association between multimorbidity and severe 
SARS-CoV-2 infection was estimated using logistic 
regression models. The odds ratio (OR) and 95% confi-
dence intervals (CI) were reported comparing multimor-
bidity versus no multimorbidity (reference). Models were 
adjusted for age at test, sex, ethnicity, deprivation, smok-
ing status, BMI, air pollution, serum 25‐hydroxyvitamin 
D, cardiorespiratory fitness, serum C-reactive protein, 
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season at blood draw [categorised by the months: spring 
(March, April, May), summer (June, July, August), 
autumn (September, October, November), and win-
ter (December, January, February)], and regular intake 
of vitamin D supplement (yes or no). Stratified analyses 
were used for the ten potential effect modifiers, and we 
tested for interaction effects using a Likelihood ratio test 
and the related P-value.
In sensitivity analyses to assess the robustness of our 
results, we repeated the stratified analyses using 3 or 
more comorbid conditions. Moreover, we further strati-
fied the analyses using four 25‐hydroxyvitamin D lev-
els (< 25, 25–50, 50–75, > 75  nmol/L) and also included 
a more recent testing phase for 25‐hydroxyvitamin D 
levels; and we used the air pollution level markers  NO2 
and PM 2.5 at the last recorded measure. Since the other 
potential confounders were measured only once prior 
to the pandemic, we additionally accounted for the time 
between the baseline data collection and the date of hos-
pitalisation of SARS-CoV-2, mortality, or censoring. In 
addition, the adjustment for cardiorespiratory fitness 
and level of serum C-reactive protein could be seen as 
a consequence of co-morbidities, therefore we assessed 
the results with these potential mediators removed. A 
P-value less than 0.05 was considered statistically signifi-
cant. All analyses were performed in Stata version 16.0.
Results
Participant characteristics
In 360,283 UK Biobank participants, 1706 (0.5%) had 
severe SARS-CoV-2 infection. The median [range] age 
was 68 [48–85] years and most participants were White 
(94.5%). Compared with participants without severe 
SARS-CoV-2 infection, those with severe infection were 
older (≥ 60  years: 86% vs. 77%), mainly men (58% vs. 
46%), more likely to live in deprived areas (60% vs. 50%), 
with higher mean BMI (28.6 kg/m2 vs 27.4 kg/m2), were 
current or previous smokers, had vitamin D deficiency 
(16% vs.12%), and more frequently reported a slow walk-
ing pace (17% vs. 7%); Table 1.
Pattern of multimorbidity
The most prevalent pre-existing multimorbidity index 
conditions in those with severe SARS-CoV-2 infection 
were hypertension (39.6%), asthma (13.3%), diabetes 
(10.0%), cancer (9.9%), and angina (6.5%; Table 2). There 
was a higher prevalence of hypertension (39.6% vs. 25.3%) 
and diabetes (10% vs. 3.9%) in individuals with severe 
SARS-CoV-2 infection compared to those without. The 
prevalence of multimorbidity (2 or more conditions) was 
over double in those with severe SARS-CoV-2 infection 
(25.3%) compared to those without severe SARS-CoV-2 
infection (11.6%; Table  2), where the most common 
clusters were found in those with both stroke and hyper-
tension (79% of those with stroke had hypertension), 
diabetes and hypertension (72% of those with diabetes), 
CKD and hypertension (68% of those with CKD), angina 
and hypertension (67% of those with angina; Fig. 1). The 
trend of severe SARS-CoV-2 infection cases in this study 
peaked at the end of March and beginning of April 2020, 
and those with multimorbidity had a consistently higher 
proportion of cases during the period compared to those 
without multimorbidity; Fig. 2.
Risk of severe SARS‑CoV‑2 infection
The risk of severe SARS-CoV-2 infection increased with 
the number of pre-existing multimorbidity index con-
ditions, illustrated by the higher odds ratios across the 
number of increasing conditions (Table  3). The overall 
combined effect in those with multimorbidity (2 or more 
conditions) was associated with around 2.6 times greater 
risk of severe SARS-CoV-2 infection compared to those 
without multimorbidity (crude OR 2.56 [2.32, 2.89]); and, 
in the adjusted model, nearly two times greater (adjusted 
OR 1.91 [1.70, 2.15]), Table 3. The odds ratios remained 
generally consistent with the overall associations when 
estimated across strata of effect modifiers (Fig.  3). The 
association was stronger in those over the age of 60 years 
compared to under 60 years, and slightly stronger in men 
compared to women (Fig. 3). It was also apparent that the 
risk differed across the most common clusters of multi-
morbidity (Table  4) with clusters containing asthma & 
hypertension having the lowest risk (adjusted OR 1.29 
[1.03, 1.60]) and those containing CKD & diabetes having 
the highest risk (adjusted OR 4.93 [3.36, 7.22]).
Results were consistent in sensitivity analyses con-
sidering the following: (1) when examining the associa-
tion between the multimorbidity index using 3 or more 
comorbid conditions and the risk of severe SARS-CoV-2 
infection, however the interaction effect between men 
and women was non-significant; (2) when assessing the 
25OH-vitamin D levels using further stratifications; (3) 
and at a later phase; (4) when using the last recorded 
air pollution  NO2 and PM 2.5 levels; (4) after adjusting 
for the time difference; and (5) when removing the con-
founders cardiorespiratory fitness and level of serum 
C-reactive protein (see Additional file  1: Tables S2, S3, 
and S4).
Discussion
Our review of the published literature indicated that the 
most commonly reported chronic conditions for severe 
SARS-CoV-2 infection were cardiometabolic diseases. 
Data from the UK Biobank study using the multimorbid-
ity index conditions showed that 25% of those with severe 
SARS-CoV-2 infection had multimorbidity (2 or more 
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conditions). The major clusters were stroke and hyper-
tension; diabetes and hypertension; CKD and hyperten-
sion; and angina and hypertension. Over the study period 
the risk of severe SARS-CoV-2 infection was consistently 
higher for those with multimorbidity compared to those 
without multimorbidity. Moreover, our results highlight 
that the greater risk of severe infection was consistent 
with that of the overall effect of multimorbidity when 
Table 1 Characteristics of UK Biobank participants
N (%) presented, unless stated otherwise. Deprivation defined by Townsend deprivation index. P-values calculated by t-test or Chi squared test
NO2 nitrogen dioxide
a Severe SARS-CoV-2 infection included those with a positive test result for SARS-CoV-2 with hospitalisation, or those who died during the study period (16 March to 
26 July, 2020)
b Those without severe SARS-CoV-2 infection included those who had not been tested, or who had tested negative for SARS-CoV-2
Characteristics With severe SARS‑CoV‑2  infectiona
N = 1706 (0.5%)
Without severe SARS‑CoV‑2 
 infectionb
N = 358,577 (99.5%)
P value
Current age, mean [SD] 71.0 [8.0] 67.2 [8.1]  < 0.001
  < 60 years 248 (14.5) 83,021 (23.2)
  ≥ 60 years 1458 (85.5) 275,556 (76.9)  < 0.001
Sex
 Women 725 (42.5) 194,846 (54.3)
 Men 981 (57.5) 163,731 (45.7)  < 0.001
Ethnicity
 White 1567 (91.9) 339,052 (94.6)
 Non-white 139 (8.2) 19,525 (5.5)  < 0.001
Deprivation index, mean [SD] − 0.6 [3.4] − 1.4 [3.0]
 Least deprived 699 (41.0) 179,448 (50.0)
 Most deprived 1007 (59.0) 179,129 (50.0)  < 0.001
Body mass index (kg/m2), mean [SD] 28.6 [5.3] 27.4 [4.7]
 Normal (18.5–24.9 kg/m2) 426 (25.0) 120,338 (33.6)
 Overweight (25–29.9 kg/m2) 729 (42.7) 153,185 (42.7)  < 0.001
 Obese (≥ 30 kg/m2) 551 (32.3) 85,054 (23.7)
Smoking status
 Never 772 (45.3) 199,897 (55.8)
 Previous 699 (41.0) 124,183 (34.6)
 Current 235 (13.8) 34,497 (9.6)  < 0.001
Air pollution  NO2 (μg/m
3) mean [SD] 29.5 [8.8] 28.0 [8.6]
 Low/moderate level (< 40 μg/m3) 1547 (90.7) 333,831 (93.1)
 High level (≥ 40 μg/m3) 159 (9.3) 24,746 (6.9)  < 0.001
25(OH) D (nmol/L), mean [SD] 47.3 [21.6] 49.6 [21.0]
 Severe deficiency (< 25 nmol/L) 278 (16.3) 43,280 (12.1)
 Sufficient (≥ 25 nmol/L) 1428 (83.7) 315,297 (87.9)  < 0.001
Regular vitamin D supplements intake 81 (4.8) 14,295 (4.0) 0.109
Season of blood draw
 Winter 328 (19.2) 66,579 (18.6)
 Spring 491 (28.8) 99,791 (27.8)
 Summer 490 (28.7) 104,251 (29.1)
 Autumn 397 (23.3) 87,956 (24.5) 0.548
Walking pace
 Slow pace 290 (17.0) 25,279 (7.1)
 Steady/brisk pace 1416 (83.0) 333,298 (93.0)  < 0.001
C-reactive protein (mg/L), mean [SD] 3.3 [5.4] 2.5 [4.1]
 Normal (< 3 mg/L) 1213 (71.1) 281,507 (78.5)
 High (≥ 3 mg/L) 493 (28.9) 77,070 (21.5)  < 0.001
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stratifying by the potential effect modifiers. The only 
exception was when stratifying by age, with a greater 
magnitude of association between multimorbidity and 
severe infection in those over 60 years compared to those 
under 60  years. Although a statistically significant dif-
ference was also found by sex (P = 0.020), the estimated 
odds ratios were similar in both men and women, indi-
cating less clinical importance for this modifier. The 
association between the most common co-occurring 
multimorbidity clusters and risk of severe SARS-CoV-2 
infection was strongly evidenced in those with pre-exist-
ing CKD and diabetes.
To our knowledge, this is the first study to develop a 
multimorbidity index using the most common conditions 
from the current COVID-19 literature. There have been 
three previously published studies that assessed the asso-
ciation between multimorbidity and the risk of SARS-
CoV-2 infection. The first was an online questionnaire 
study by 26 hospitals across Italy undertaken in March 9 
to April 9, 2020, with a total of 1591 participants admit-
ted with SARS-CoV-2 infection (188 non-survivors, 1403 
survivors) [14]. The study used the Charles Comorbidity 
Index (CCI) which takes into account age and 19 condi-
tions in an algorithm to predict 10-year mortality. The 
authors found an exponential increase in the odds by each 
point of the CCI score [14]. Our multimorbidity index 
found similar results since the risk of severe SARS-CoV-2 
infection increased with the number of pre-existing mul-
timorbidity index conditions. Two studies were based in 
UK Biobank, however the study design and outcomes dif-
fered which resulted in inconsistent findings. One study 
in 4510 UK Biobank participants between 16 March to 
1 June, 2020 (1326 tested positive for COVID-19 and 
3184 tested negative) found in adjusted analyses that the 
number of comorbidity groupings (0–1, 2, 3, ≥ 4) was not 
associated with the risk of testing positive for COVID-
19 when compared to those who tested negative: the OR 
was 1.0 [95% CI 0.8, 1.2] comparing those with 2 condi-
tions vs. 0–1 conditions; or only slightly increased when 
compared to the remaining population (OR 1.3 [1.1, 1.5]) 
[13]. However, this study used 43 different conditions to 
define multimorbidity, and compared only those testing 
Table 2 Multimorbidity index conditions among participants in the UK Biobank Study
P-values calculated by chi squared test
a Severe SARS-CoV-2 infection included those with a positive test result for SARS-CoV-2 with hospitalisation, or those who died during the study period (16 March to 
26 July, 2020)
b Those without severe SARS-CoV-2 infection included those who had not been tested, or who had tested negative for SARS-CoV-2
Multimorbidity index conditions With severe SARS‑CoV‑2 
 infectiona
N = 1706 (0.5%)
Without severe SARS‑CoV‑2 
 infectionb
N = 358,577 (99.5%)
P value
Hypertension 676 (39.6) 90,747 (25.3)  < 0.001
Asthma 226 (13.3) 41,382 (11.5) 0.028
Diabetes 170 (10.0) 14,079 (3.9)  < 0.001
Cancer 179 (10.5) 27,108 (7.6)  < 0.001
Angina 111 (6.5) 10,037 (2.8)  < 0.001
Myocardial infarction 102 (6.0) 7096 (2.0)  < 0.001
Chronic kidney disease 93 (5.5) 7188 (2.0)  < 0.001
Stroke 47 (2.8) 3957 (1.1)  < 0.001
Atrial fibrillation 26 (1.5) 2508 (0.7)  < 0.001
Chronic obstructive pulmonary disease 14 (0.8) 929 (0.3)  < 0.001
Heart failure 5 (0.3) 146 (0.04)  < 0.001
Peripheral vascular disease 4 (0.2) 595 (0.2) 0.488
Number of multimorbidity index conditions
 None 683 (40.0) 206,012 (57.5)
 One 592 (34.7) 111,153 (31.0)
 Two 293 (17.2) 32,059 (8.9)
 Three 96 (5.6) 7341 (2.1)
 Four 27 (1.6) 1646 (0.5)
 Five 12 (0.7) 311 (0.1)
 Six 2 (0.1) 47 (0.01)
 Seven 1 (0.1) 7 (0.0)
 Eight 0 (0.0) 1 (0.0)  < 0.001
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positive compared to negative. The other UK Biobank 
study, between 16 March and 18 May, 2020 (1324 tested 
positive for COVID-19 and 426,875 remaining cohort), 
used Poisson regression analyses reporting that those 
with multimorbidity (defined using 43 conditions) had a 
48% higher risk for a positive test for COVID-19 (RR 1.48 
[95% CI 1.28, 1.71], P < 0.01). Although this study also 
reported that those with cardiometabolic multimorbidity, 
compared with those without, had a 77% higher risk for 
a positive test (RR 1.77 [1.46, 2.15] P < 0.01) [15], the out-
come was based on testing positive in any setting (hos-
pital or outpatient, pillar 1 and 2), which may introduce 
testing bias within UK Biobank. A recent article illus-
trated how the same dataset can produce apparently 
paradoxical findings for the same outcome [34]. For this 
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Fig. 1 Two most common pre-existing multimorbidity index conditions in UK Biobank participants with and without severe SARS-CoV-2 infection 





















Without multimorbidity With multimorbidity
Fig. 2 Comparing the prevalence and date of those diagnosed with severe SARS-CoV-2 infection (hospitalisation or death, N = 1706) by 
multimorbidity index (≥ 2 conditions) in the UK Biobank. Without multimorbidity (n = 1275); with multimorbidity (n = 431). Multimorbidity index 
conditions include: angina, asthma, atrial fibrillation, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, heart 
failure, hypertension, myocardial infarction, peripheral vascular disease, and stroke
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with severe SARS-CoV-2 infection; hospitalisation or 
death during the pandemic compared to the remaining 
cohort. Moreover, the three studies to date have only pre-
sented the number of conditions but have not examined 
the patterns of multimorbidity, i.e. the type of the two 
most common co-occurring conditions found in those 
with severe SARS-CoV-2 infection, nor the rate of severe 
infection or mortality in people with multimorbidity over 
the period of the pandemic.
Hypertension was found to be the most prevalent con-
dition (40%) in those with severe SARS-CoV-2 infec-
tion, as in a number of previously published studies. Yet, 
when examined by clusters, we found that hypertension 
mainly co-existed with other conditions (i.e. diabetes, 
stroke, CKD). Thus, certain clusters of the multimorbid-
ity index are more frequent than other clusters. When 
examining the association between the most common 
co-occurring multimorbidity clusters and the risk of 
severe SARS-CoV-2 infection, those with pre-existing 
CKD and diabetes showed the strongest association. For 
this reason, we believe that the classification of those 
with pre-existing multimorbidity index conditions is 
crucial to provide prognostic information to tailor effec-
tive treatment and prevent severe outcomes in com-
mon chronic conditions. Individuals with pre-existing 
multimorbidity conditions may have potential organ 
dysfunctions, which are further accelerated by the local 
and systemic effects related to SARS-CoV-2 infection. 
Previous studies have investigated the possible patho-
physiological mechanisms linking this infection to severe 
COVID-19 syndrome, including increased inflammation, 
decreased immune response, heart failure, renal failure, 
and potentially multi-system organ failure and death [35, 
36]. Further research is however required to understand 
the underlying biological mechanisms involved between 
these multimorbidity clusters and the increased risk of 
severe COVID-19 and its long-term sequelae (i.e., “long 
COVID”), particularly the effects on the immune system 
and frailty.
Multimorbidity has been associated with premature 
mortality, lower quality of life, polypharmacy, frailty, 
and fragmented care [10]. However, the current pan-
demic has placed additional risks on individuals with 
multimorbidity. A global survey evaluating the impact 
of COVID-19 on routine care for chronic diseases dur-
ing 31 March to 23 April 2020 found that most health-
care professionals (67%) identified moderate or severe 
effects on their patients due to changes in healthcare 
services since the outbreak; and 80% reported the mental 
health of their patients worsened during COVID-19 [37]. 
Moreover, many low and middle-income countries have 
overstretched healthcare systems and the pandemic has 
further overwhelmed them.
A key strength of this study is the overall large sam-
ple size which allowed us to investigate whether the 
associations were heterogeneous across clinically rel-
evant effect modifiers. We employed a comprehensive 
list of effect modifiers, extending past research [4], 
and enabling a greater understanding of the associa-
tion between multimorbidity and severe SARS-CoV-2 
infection. Moreover, we performed a literature review 
to derive an evidence based COVID-19 relevant mul-
timorbidity index which can be applied to other popu-
lations [5–8, 20–29]. This study has some limitations. 
Issues of the low response rate (~ 5%) and selection 
bias, such as slightly higher representation of partici-
pants from affluent groups may suggest that the UK 
Biobank sample is not well representative of the UK 
population, and have been discussed previously [38]. 
The characteristics we examined were recorded at 
recruitment, representing data collected in the past at 
study baseline, but we conducted additional sensitiv-
ity analyses using the follow-up data for 25‐hydroxy-
vitamin D levels and the last recorded air pollution 
 (NO2) data, showing consistent results over time. In 
further sensitivity analyses, we additionally adjusted 
the model for the time in the study, and found the 
results remained consistent. Factors such as cardiores-
piratory fitness or C-reactive protein could possibly 
be a consequence of poor health from multimorbid-
ity instead of cause, for this reason we removed these 
from the model, and the results remained the same. The 
data on multimorbidity were appraised only at base-
line but there may have been a change in the number 
of multimorbidity index conditions since recruitment 
which were not accounted for and may lead to under or 
Table 3 Association between the number of multimorbidity 
index conditions and the risk of severe SARS-CoV-2 infection: UK 
Biobank (N = 360,283)
Multimorbidity index conditions include: angina, asthma, atrial fibrillation, 
cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes 
mellitus, heart failure, hypertension, myocardial infarction, peripheral vascular 
disease, and stroke
Models adjusted for age at test, sex, ethnicity, deprivation, smoking status, 
body mass index, air pollution, 25‐hydroxyvitamin D, cardiorespiratory fitness, 
C-reactive protein, season at blood draw, and regular intake of vitamin D 
supplement
OR odds ratio, CI confidence interval




Crude OR (95% CI) Adjusted OR (95% CI)
 ≥ 1 vs. 0 (reference) 2.02 (1.84, 2.23) 1.65 (1.49, 1.82)
 ≥ 2 vs. < 2 (reference) 2.59 (2.32, 2.89) 1.91 (1.70, 2.15)
 ≥ 3 vs. < 3 (reference) 3.29 (2.76, 3.92) 2.02 (1.68, 2.43)
 ≥ 4 vs. < 4 (reference) 4.47 (3.28, 6.09) 2.25 (1.64, 3.09)
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overestimation of effect. We were unable to assess the 
severity of disease conditions but our new multimor-
bidity index definition included conditions that were 
most relevant to COVID-19. Another limitation is the 
lack of detail of clinical severity of those with severe 
SARS-CoV-2 infection: while we have accounted for 
Fig. 3 Association between the multimorbidity index and risk of severe SARS-CoV-2 infection across strata of effect modifiers (N = 360,283) in 
the UK Biobank Study. Odds ratios comparing subjects with multimorbidity (≥ 2 conditions) vs without multimorbidity (reference: < 2 conditions). 
P-values tested for interaction. OR odds ratio; CI confidence interval; NO2 nitrogen dioxide. Multimorbidity index conditions include: angina, asthma, 
atrial fibrillation, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, heart failure, hypertension, myocardial 
infarction, peripheral vascular disease, and stroke. Models adjusted for age at test, sex, ethnicity, deprivation, smoking status, body mass index, air 
pollution, 25‐hydroxyvitamin D, cardiorespiratory fitness, C-reactive protein, season at blood draw, and regular intake of Vitamin D supplement
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hospitalisation or death during the pandemic, further 
details of adverse COVID-19 outcomes such as length 
of hospital stay, intensive care admission, or mechani-
cal ventilation, could provide further information. Ten 
potential effect modifiers were selected [4], although 
there are other factors which could possibly modify the 
association between multimorbidity and risk of severe 
SARS-CoV-2 infection but were unaccounted for, such 
as household size, occupation, and understanding 
and behaviour for social distancing, shielding, wear-
ing facemasks and hand hygiene. Finally, this was an 
observational study, which limits our ability to establish 
causality.
Conclusion
In conclusion, having a new multimorbidity COVID-
19 index that may help identify subjects at higher risk 
of complication in clinical practice could be beneficial. 
Where stratifying the risk according to the presence of 
multimorbidity, and reinforcing initiatives and resources 
to reduce the risk in this vulnerable group of individuals 
should be considered as priorities in the current corona-
virus pandemic.
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